<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">REMEDIUM</journal-id><journal-title-group><journal-title>REMEDIUM</journal-title></journal-title-group><issn publication-format="print">1561-5936</issn><issn publication-format="electronic">2658-3534</issn><publisher><publisher-name>Joint-Stock Company Chicot</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">850</article-id><article-id pub-id-type="doi">10.21518/1561-5936-2021-2-25-29</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Russian pharmaceutical market as of the first quarter, 2021</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kalinina</surname><given-names>Nadezhda</given-names></name><bio></bio><email>-</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shestovets</surname><given-names>Anastasiya</given-names></name><bio></bio><email>-</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">RM Analytics</aff><pub-date date-type="epub" iso-8601-date="2021-12-14" publication-format="electronic"><day>14</day><month>12</month><year>2021</year></pub-date><issue>2</issue><fpage>25</fpage><lpage>29</lpage><history><pub-date date-type="received" iso-8601-date="2022-03-17"><day>17</day><month>03</month><year>2022</year></pub-date></history><permissions><copyright-statement>Copyright © 2021,</copyright-statement><copyright-year>2021</copyright-year></permissions><abstract>Since a partially unfavourable epidemiological situation persists, the Russian pharmaceutical market remains one of the most steadily growing in terms of roubles. Feverish demand for drugs, enhancement of the role of the public segment, increase in importance and speed of adoption of legislative initiatives – all these factors have a significant impact on both the dynamics and conditions of the broader market, becoming not only a strength test for the pharmaceutical industry, but also a chance to implement new opportunities.</abstract><kwd-group xml:lang="en"><kwd>russian pharmaceutical market</kwd><kwd>pharmacy segment</kwd><kwd>hospital purchases</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>российский фармацевтический рынок</kwd><kwd>аптечный сегмент</kwd><kwd>госпитальные закупки</kwd></kwd-group></article-meta></front><body></body><back/></article>
